ProCE Banner Activity

CE / CME

Evolving Treatment Strategies for CLL/SLL and MCL

Interactive Video Lecture

Treatment options for B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and mantle cell lymphoma (MCL) are rapidly changing with the addition of Bruton's tyrosine kinase (BTK) inhibitors ibrutinib, acalabrutinib, and zanubrutinib, as well as the BCL2 inhibitor venetoclax. This activity provides expert advice on how to select preferred treatment regimens for your patients with CLL/SLL and MCL, as well as manage treatment-related adverse events to provide optimal care.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: January 31, 2022

Expiration: January 30, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Acknowledgement

This program was cosupported by educational grants from Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

This activity is supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Novartis Pharmaceuticals Corporation.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify novel therapies for treatment of CLL/SLL and MCL

  • Formulate evidence-based approaches for individualization of therapy in CLL/SLL and MCL

  • Apply strategies to appropriately manage treatment-associated toxicities in CLL/SLL and MCL

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Faiman has no relevant financial relationships to disclose.

Ms Sandy: fees for non-CME/CE services: Amgen, AstraZeneca, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

CME Info

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: January 31, 2022
Expiration date: January 30, 2023

Format

Interactive video lecture

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 30, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.